# To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

> **NCT04770935** · PHASE1 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 6 (actual)

## Conditions studied

- Von Willebrand's Disease (VWD)

## Interventions

- **DRUG:** efanesoctocog alfa (BIVV001)

## Key facts

- **NCT ID:** NCT04770935
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-20
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770935, "To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04770935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*